Amatu A, Sartore-Bianchi A, Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open. 2016;1: e000023.

Article  PubMed  PubMed Central  Google Scholar 

Solomon JP, Linkov I, Rosado A, Mullaney K, Rosen EY, Frosina D, et al. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls. Mod Pathol. 2020;33:38–46.

Article  PubMed  CAS  Google Scholar 

Demetri GD, De Braud F, Drilon A, Siena S, Patel MR, Cho BC, et al. Updated integrated analysis of the efficacy and safety of Entrectinib in patients With NTRK fusion-positive solid tumors. Clin Cancer Res. 2022;28:1302–12.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Yao KJ, Jabbour S, Parekh N, Lin Y, Moss RA. Increasing mortality in the United States from cholangiocarcinoma: an analysis of the National Center for Health Statistics Database. BMC Gastroenterol. 2016;16:117.

Article  PubMed  PubMed Central  Google Scholar 

Kim Y, Moris DP, Zhang X-F, Bagante F, Spolverato G, Schmidt C, et al. Evaluation of the 8th edition American Joint Commission on Cancer (AJCC) staging system for patients with intrahepatic cholangiocarcinoma: A surveillance, epidemiology and end results (SEER) analysis. J Surg Oncol. 2017;116:643–50.

Article  PubMed  Google Scholar 

Benson AB 3rd, D’Angelica MI, Abrams TA, Are C, Bloomston PM, Chang DT, et al. Hepatobiliary cancers, version 2.2014. J Natl Compr Canc Netw. 2014;12:1152–82.

Article  PubMed  CAS  Google Scholar 

Nakamura H, Arai Y, Totoki Y, Shirota T, Elzawahry A, Kato M, et al. Genomic spectra of biliary tract cancer. Nat Genet. 2015;47:1003–10.

Article  PubMed  CAS  Google Scholar 

Rizzo A, Ricci AD, Brandi G. IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver? Cancer Treat Res Commun. 2021;27: 100356.

Article  PubMed  Google Scholar 

Zhu AX, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, et al. Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy Trial. JAMA Oncol. 2021;7:1669–77.

Article  PubMed  Google Scholar 

Jiang Q, Li M, Li H, Chen L. Entrectinib, a new multi-target inhibitor for cancer therapy. Biomed Pharmacother. 2022;150: 112974.

Article  PubMed  CAS  Google Scholar 

Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol. 2020;21:271–82.

Article  PubMed  CAS  Google Scholar 

Skaper SD. The biology of neurotrophins, signalling pathways, and functional peptide mimetics of neurotrophins and their receptors. CNS Neurol Disord Drug Targets. 2008;7:46–62.

Article  PubMed  CAS  Google Scholar 

Liu D, Flory J, Lin A, Offin M, Falcon CJ, Murciano-Goroff YR, et al. Characterization of on-target adverse events caused by TRK inhibitor therapy. Ann Oncol. 2020;31:1207–15.

Article  PubMed  CAS  Google Scholar 

Martineau C, Turcotte M-K, Otis N, Provost F, Themens L, Guay M-P, et al. Management of adverse events related to first-generation tyrosine receptor kinase inhibitors in adults: a narrative review. Support Care Cancer. 2022;30:10471–82.

Article  PubMed  Google Scholar